熱門資訊> 正文
ImmuCell报告第一季度业绩
2024-05-15 04:48
- ImmuCell press release (NASDAQ:ICCC): Q1 net loss was $438,000, or $0.06 per basic share.
- Product sales increased by 111%, or $3.8 million, to $7.3 million during the three-month period ended March 31, 2024 compared to $3.4 million during the three-month period ended March 31, 2023.
More on ImmuCell
- ImmuCell Corporation (ICCC) Q4 2023 Earnings Call Transcript
- ImmuCell reports preliminary Q1 sales, stock climbs 7%
- Financial information for ImmuCell
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
